Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial-Reference-Cited by-同舟云学术

Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial

Published:2023-09 Issue:10405 Volume:402 Page:859-870
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Lafayette Richard,Kristensen Jens,Stone Andrew,Floege Jürgen,Tesař Vladimir,Trimarchi Hernán,Zhang Hong,Eren Necmi,Paliege Alexander,Reich Heather N,Rovin Brad H,Barratt Jonathan

Publisher

Elsevier BV

Subject

General Medicine

Reference25 articles.

1. IgA nephropathy;Wyatt;N Engl J Med,2013

2. Recent advances in the understanding and management of IgA nephropathy;Lai;F1000 Res,2016

3. Prognosis in IgA nephropathy: 30-year analysis of 1012 patients at a single center in Japan;Moriyama;PLoS One,2014

4. A retrospective analysis of the natural history of primary IgA nephropathy worldwide;Schena;Am J Med,1990

5. Immunosuppressive agents for treating IgA nephropathy;Vecchio;Cochrane Database Syst Rev,2015

Cited by 69 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pathogenic Immunoglobulin A-Producing Cells in Immunoglobulin A Nephropathy;Journal of Clinical Medicine;2024-09-05

2. The pathogenesis of IgA nephropathy and implications for treatment;Nature Reviews Nephrology;2024-09-04

3. Kinpeygo for the treatment of primary immunoglobulin A nephropathy;Prescriber;2024-09

4. Exploring Novel Adverse Events of Nefecon;Kidney International Reports;2024-09

5. Long-term renal survival in patients with IgA nephropathy: a systematic review;Renal Failure;2024-08-27